Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CLSN

Imunon (CLSN) Stock Price, News & Analysis

Imunon logo

About Imunon Stock (NASDAQ:CLSN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.95
$2.63
52-Week Range
N/A
Volume
711 shs
Average Volume
150,471 shs
Market Capitalization
$13.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Receive CLSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

CLSN Stock News Headlines

Imunon Inc IMNN
CLSN.L Regulatory News
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Headlines

CLSN Stock Analysis - Frequently Asked Questions

Imunon, Inc. (NASDAQ:CLSN) announced its earnings results on Monday, August, 15th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.12) by $0.25. Imunon had a negative net margin of 5,229.80% and a negative trailing twelve-month return on equity of 50.18%.

Imunon shares reverse split on Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Acasti Pharma (ACST), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
8/15/2022
Today
5/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CLSN
Employees
27
Year Founded
1982

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-20,770,000.00
Net Margins
-5,229.80%
Pretax Margin
-5,506.60%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Price / Cash Flow
N/A
Book Value
$9.66 per share
Price / Book
N/A

Miscellaneous

Free Float
6,768,000
Market Cap
$13.91 million
Optionable
Optionable
Beta
2.27

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:CLSN) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners